PF-06700841
Phase 2Small molecule
PfizerPF-06700841 is one of 223 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.
8
Indications
19
Total Trials
0
Active Trials
222
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisPreclinical
Stelara
Johnson & JohnsonPreclinical
Taltz
Eli LillyPreclinical
PF-06700841
PfizerPhase 2
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Ilumya
Sun Pharmaceutical Industries, Inc.Preclinical
Raptiva
RochePreclinical
Siliq
BBausch Health Americas, Inc.
Preclinical
Victoza
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Psoriasis2 trials
Tics2 trials
Moderate to Severe Crohn's Disease1 trial
Alopecia Areata1 trial
11 more indications
Hidradenitis Suppurativa1 trial
Ulcerative Colitis1 trial
Atopic Dermatitis1 trial
Single Dose1 trial
Psoriatic Arthritis1 trial
Systemic Lupus Erythematosus1 trial
Irritation1 trial
Concentration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PF-06700841. EMBL-EBI & Wellcome Sanger Institute.
- [4]